OmniAb, Inc. (OABI) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the OABI SEC filings page.
OmniAb, Inc. (OABI) reported $38.5M in revenue over the twelve months to Jun 30, 2026, up 67.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
OmniAb remains a development-stage business, where shrinking revenue and persistent R&D spending keep operating losses structurally high.
In FY2025, a operating loss of$69.0M translated into operating cash flow of-$36.5M , so accounting losses materially exceeded the cash outflow. With capital expenditures of only$565K and free cash flow of-$37.0M , the gap is better explained by noncash charges than by heavy reinvestment.
Revenue fell from
The balance sheet is lightly liability-funded: FY2025 liabilities were
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of OmniAb, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
OmniAb, Inc. held $54.0M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $36.5M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and OmniAb, Inc. scores 42/100 among other emerging companies.
OmniAb, Inc. had 145M shares outstanding at the end of fiscal year 2025, against 122M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and OmniAb, Inc. scores 46/100 among other emerging companies.
OmniAb, Inc. spent $47.8M on research and development in fiscal year 2025, which was 54.5% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and OmniAb, Inc. scores 80/100 among other emerging companies.
OmniAb, Inc. reported revenue of $18.7M in fiscal year 2025, against $26.4M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and OmniAb, Inc. scores 15/100 among other emerging companies.
Not available for OmniAb, Inc., and counted as zero in the overall score.
OmniAb, Inc.'s cash, cash equivalents and investments came to $54.0M at the end of fiscal year 2025, against $33.9M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and OmniAb, Inc. scores 70/100 among other emerging companies.
OmniAb, Inc. scores 11.06, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($696.4M) relative to total liabilities ($33.9M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
OmniAb, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
OmniAb, Inc. reported a net loss of $64.8M while operations used $36.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
OmniAb, Inc. generated $13.4M in revenue in Q2 2026. This represents an increase of 244.2% from the same quarter a year earlier. Against the prior quarter it is down 7.0%.
OmniAb, Inc.'s EBITDA was -$3.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 75.5% from the same quarter a year earlier. Against the prior quarter it is down 149.7%.
OmniAb, Inc. reported -$5.9M in net income in Q2 2026. This represents an increase of 63.1% from the same quarter a year earlier. Against the prior quarter it is up 24.0%.
OmniAb, Inc. earned -$0.05 per diluted share (EPS) in Q2 2026. This represents an increase of 66.7% from the same quarter a year earlier. Against the prior quarter it is up 16.7%.
Cash & Balance Sheet
OmniAb, Inc. generated $2.6M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 148.4% from the same quarter a year earlier. Against the prior quarter it is up 150.6%.
OmniAb, Inc. held $24.3M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
OmniAb, Inc.'s operating margin was -49.5% in Q2 2026, reflecting core business profitability. Against the prior quarter it is up 4.8 percentage points. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
OmniAb, Inc.'s net profit margin was -43.7% in Q2 2026, showing the share of revenue converted to profit. Against the prior quarter it is up 9.8 percentage points. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
OmniAb, Inc.'s ROE was -2.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 3.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.7 percentage points.
Not reported for Q2 2026.
Capital Allocation
OmniAb, Inc. invested $9.6M in research and development in Q2 2026. This represents a decrease of 11.8% from the same quarter a year earlier. Against the prior quarter it is down 0.6%.
OmniAb, Inc. invested $110K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 33.3% from the same quarter a year earlier. Against the prior quarter it is down 34.1%.
Not reported for Q2 2026.
OABI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.4M+244.2% | $14.4M+247.3% | $8.4M-22.5% | $2.2M-46.3% | $3.9M-48.8% | $4.2M+9.3% | $10.8M+124.1% | $4.2M-23.8% |
| R&D Expenses | $9.6M-11.8% | $9.6M-23.5% | $13.9M+4.5% | $10.4M-22.1% | $10.9M-22.0% | $12.6M-13.4% | $13.3M-9.9% | $13.3M-4.0% |
| SG&A Expenses | $6.7M-13.4% | $6.6M-16.4% | $6.8M-7.1% | $6.8M-4.3% | $7.7M-3.5% | $7.9M-5.1% | $7.4M-6.5% | $7.1M-16.8% |
| Operating Income | -$6.6M+59.1% | -$7.8M+58.5% | -$15.8M+0.7% | -$18.1M+8.2% | -$16.2M+0.5% | -$18.8M+16.4% | -$15.9M+25.1% | -$19.8M+2.7% |
| EBITDA | -$3.0M+75.5% | -$1.2M+91.5% | -$6.9M+5.1% | -$14.0M+8.8% | -$12.2M-14.3% | -$14.1M+19.9% | -$7.3M+52.5% | -$15.4M+3.4% |
| Income Tax | -$353K-396.6% | $442K+517.0% | -$367K+83.0% | -$1.2M+57.1% | $119K+106.3% | -$106K+95.9% | -$2.2M+63.9% | -$2.7M+18.0% |
| Net Income | -$5.9M+63.1% | -$7.7M+57.7% | -$14.2M-8.5% | -$16.5M-0.9% | -$15.9M-16.5% | -$18.2M+4.0% | -$13.1M+7.0% | -$16.4M-4.0% |
| EPS (Basic) | -$0.05+66.7% | -$0.06+64.7% | -$0.11+15.4% | -$0.14+12.5% | -$0.15-15.4% | -$0.17+10.5% | -$0.13+7.1% | -$0.160.0% |
| EPS (Diluted) | -$0.05+66.7% | -$0.06+64.7% | -$0.11+15.4% | -$0.14+12.5% | -$0.15-15.4% | -$0.17+10.5% | -$0.13+7.1% | -$0.160.0% |
| Diluted Shares (Avg) | 129M+21.3% | 128M+21.4% | N/A | 115M+12.0% | 106M+4.6% | 106M+4.8% | N/A | 102M+2.5% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
OABI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $290.3M-1.8% | $293.6M-4.1% | $300.9M-7.6% | $309.7M-6.6% | $295.7M-12.3% | $306.2M-13.2% | $325.6M-13.2% | $331.6M-15.4% |
| Current Assets | $66.0M+38.6% | $65.1M+21.6% | $65.3M-4.1% | $66.3M-0.4% | $47.6M-29.2% | $53.6M-30.2% | $68.1M-28.2% | $66.6M-37.7% |
| Cash & Equivalents | $24.3M+33.1% | $29.0M+166.7% | $25.5M-7.5% | $28.5M+4.8% | $18.3M-12.1% | $10.9M-42.9% | $27.6M+68.7% | $27.2M+28.2% |
| Short-Term Investments | $27.7M+18.5% | $20.0M-38.8% | $28.5M-10.5% | $31.0M-3.7% | $23.3M-36.0% | $32.7M-34.5% | $31.8M-54.9% | $32.1M-57.4% |
| Inventory | $1.0M+220.6% | $920K | $823K+1614.6% | $443K | $316K | N/A | $48K | N/A |
| Accounts Receivable | $10.3M+281.7% | $12.6M+95.1% | $7.4M+40.2% | $3.1M-11.4% | $2.7M-60.6% | $6.5M+60.1% | $5.3M+37.1% | $3.5M-43.1% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $84.0M0.0% | $84.0M0.0% | $84.0M0.0% | $84.0M0.0% | $84.0M0.0% | $84.0M0.0% | $84.0M0.0% | $84.0M0.0% |
| Total Liabilities | $30.0M-10.8% | $31.0M-5.1% | $33.9M-10.7% | $32.2M-19.0% | $33.6M-22.0% | $32.7M-36.2% | $37.9M-37.4% | $39.8M-40.7% |
| Current Liabilities | $13.8M+8.9% | $13.6M+18.9% | $16.3M+7.7% | $13.3M-7.8% | $12.6M-10.7% | $11.4M-34.9% | $15.1M-34.7% | $14.4M-42.5% |
| Non-Current Liabilities | $16.2M-22.6% | $17.4M-18.0% | $17.6M-22.8% | $19.0M-25.4% | $21.0M-27.5% | $21.3M-36.8% | $22.9M-39.1% | $25.4M-39.6% |
| Total Equity | $260.3M-0.7% | $262.6M-4.0% | $267.0M-7.2% | $277.4M-4.9% | $262.1M-10.9% | $273.5M-9.2% | $287.6M-8.6% | $291.7M-10.1% |
| Retained Earnings | -$179.7M-32.7% | -$173.9M-45.4% | -$166.2M-63.9% | -$152.0M-72.1% | -$135.5M-88.3% | -$119.6M-105.0% | -$101.4M-157.6% | -$88.3M-248.9% |
Not reported in any period shown, so not listed: Long-Term Debt.
OABI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $2.7M+152.1% | -$4.9M+69.0% | -$5.7M-46.5% | -$9.8M-48.4% | -$5.1M+57.8% | -$15.9M+6.8% | -$3.9M+57.5% | -$6.6M-6.1% |
| Depreciation & Amortization | $3.7M-9.3% | $6.6M+39.9% | $7.7M+1.3% | $4.1M-6.0% | $4.0M-28.6% | $4.7M-4.2% | $7.6M+54.2% | $4.4M-0.1% |
| Stock-Based Compensation | $3.2M-23.2% | $3.3M-19.4% | N/A | $4.0M-25.3% | $4.1M-23.6% | $4.1M-27.2% | N/A | $5.3M-15.9% |
| Capital Expenditures | $110K-33.3% | $167K-20.1% | $9K-80.4% | $182K+19.7% | $165K-78.0% | $209K-77.4% | $46K-57.0% | $152K-69.0% |
| Free Cash Flow | $2.6M+148.4% | -$5.1M+68.4% | -$5.7M-45.0% | -$9.9M-47.8% | -$5.3M+58.9% | -$16.1M+10.5% | -$3.9M+57.5% | -$6.7M-0.6% |
| Investing Cash Flow | -$7.6M-162.0% | $8.4M+1060.8% | $2.7M+604.2% | -$7.7M-272.3% | $12.3M-6.2% | -$878K-104.4% | $385K-91.9% | $4.4M-29.2% |
| Financing Cash Flow | $233K-1.3% | $0-100.0% | -$50K-101.3% | $27.7M+223.0% | $236K-70.6% | $44K+121.7% | $3.8M+876.0% | $8.6M+4912.3% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
OABI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -49.5% | -54.3% | -188.2% | -810.2% | -416.2% | -453.6% | -147.0% | -473.7% |
| Net Margin | -43.7% | -53.4% | -169.3% | -738.0% | -407.4% | -438.1% | -121.0% | -392.4% |
| Return on Equity | -2.3%+3.8pp | -2.9%+3.7pp | -5.3%-0.8pp | -6.0%-0.4pp | -6.1%-1.4pp | -6.7%-0.4pp | -4.5%-0.1pp | -5.6%-0.8pp |
| Return on Assets | -2.0%+3.4pp | -2.6%+3.3pp | -4.7%-0.7pp | -5.3%-0.4pp | -5.4%-1.3pp | -5.9%-0.6pp | -4.0%-0.3pp | -4.9%-0.9pp |
| Current Ratio | 4.80+1.0x | 4.80+0.1x | 4.02-0.5x | 5.00+0.4x | 3.77-1.0x | 4.70+0.3x | 4.52+0.4x | 4.63+0.4x |
| Debt-to-Equity | 0.120.0x | 0.120.0x | 0.130.0x | 0.120.0x | 0.130.0x | 0.12-0.1x | 0.13-0.1x | 0.14-0.1x |
| Asset Turnover | 0.050.0x | 0.050.0x | 0.030.0x | 0.010.0x | 0.010.0x | 0.010.0x | 0.030.0x | 0.010.0x |
| FCF Margin | 19.1% | -35.2% | -67.8%-31.6pp | -444.2% | -136.3% | -387.1% | -36.3% | -161.3% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| OmniAb, Inc. OABI | FY2025 | $18.7M | -$64.8M | N/A | $696.4M | 42/100 |
| Codexis, Inc. CDXS | FY2025 | $70.4M | -$44.0M | -62.5% | $154.4M | 60/100 |
| Silence Therapeutics Plc SLN | FY2025 | $559K | -$88.6M | N/A | $612.8M | — |
| Humacyte, Inc. HUMA | FY2025 | $2.0M | -$40.8M | N/A | $112.6M | 34/100 |
| PUMA BIOTECHNOLOGY INC PBYI | FY2025 | $228.4M | $31.1M | 13.6% | $531.2M | 69/100 |
Where OmniAb, Inc. Ranks
Frequently Asked Questions
What is OmniAb, Inc.'s annual revenue?
OmniAb, Inc. (OABI) reported $18.7M in total revenue for fiscal year 2025. This represents a -29.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is OmniAb, Inc.'s revenue growing?
OmniAb, Inc. (OABI) revenue declined by 29.3% year-over-year, from $26.4M to $18.7M in fiscal year 2025.
Is OmniAb, Inc. profitable?
No, OmniAb, Inc. (OABI) reported a net income of -$64.8M in fiscal year 2025.
What is OmniAb, Inc.'s EBITDA?
OmniAb, Inc. (OABI) had EBITDA of -$47.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is OmniAb, Inc.'s return on equity (ROE)?
OmniAb, Inc. (OABI) has a return on equity of -24.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is OmniAb, Inc.'s free cash flow?
OmniAb, Inc. (OABI) recorded an outflow of $37.0M in free cash flow during fiscal year 2025. This represents a 10.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is OmniAb, Inc.'s operating cash flow?
OmniAb, Inc. (OABI) recorded an outflow of $36.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are OmniAb, Inc.'s total assets?
OmniAb, Inc. (OABI) had $300.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are OmniAb, Inc.'s capital expenditures?
OmniAb, Inc. (OABI) invested $565K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does OmniAb, Inc. spend on research and development?
OmniAb, Inc. (OABI) invested $47.8M in research and development during fiscal year 2025.
What is OmniAb, Inc.'s current ratio?
OmniAb, Inc. (OABI) had a current ratio of 4.02 as of fiscal year 2025, which is generally considered healthy.
What is OmniAb, Inc.'s debt-to-equity ratio?
OmniAb, Inc. (OABI) had a debt-to-equity ratio of 0.13 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is OmniAb, Inc.'s return on assets (ROA)?
OmniAb, Inc. (OABI) had a return on assets of -21.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is OmniAb, Inc.'s P/E ratio?
OmniAb, Inc. (OABI) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $696.4M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is OmniAb, Inc.'s price-to-sales ratio?
OmniAb, Inc. (OABI) trades at 18.1x sales, its market capitalization divided by revenue of $38.5M revenue, trailing 12 months to June 30, 2026. The market capitalization is $696.4M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does OmniAb, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, OmniAb, Inc. (OABI) held $54.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $36.5M over that year. Dividing the one by the other, the reported balance equals about 18 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is OmniAb, Inc.'s Altman Z-Score?
OmniAb, Inc. (OABI) has an Altman Z-Score of 11.06, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is OmniAb, Inc.'s Piotroski F-Score?
OmniAb, Inc. (OABI) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are OmniAb, Inc.'s earnings high quality?
OmniAb, Inc. (OABI) reported a net loss of $64.8M while operations used $36.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is OmniAb, Inc.?
OmniAb, Inc. (OABI) scores 42 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.